EDQM anti-counterfeiting Traceability service for medicines.

Slides:



Advertisements
Similar presentations
The vital link in healthcare 1 The European Association of Pharmaceutical Full-line Wholesalers The vital link in healthcare The European Association of.
Advertisements

Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
WHO-WTO Workshop Presentation Oslo by Keith McCullough VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES.
EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.
Unique Device Identification (UDI) System for Medical Devices Dr Larry Kelly Therapeutic Goods Administration.
WHO Good Distribution Practices for Pharmaceutical Products
© APB 2012 GH – 16 th October 2012, Birmingham Annual Seminar © APB 2012 Association of the Pharmacists of Belgium Dr. Guido Hoogewijs Patient Protection.
Session 6 : Need for good governance Importance of veterinary legislation and its appropriate implementation Jean-Luc ANGOT, CVO, France 14 March 2013.
TRACK N TRACE PHARMA PACKING LINE TRACK N TRACE PHARMA PACKING LINE
Current Issues & Challenges in the Development of Pharmacopoeial Monographs: European Pharmacopoeia Dr. Susanne Keitel European Directorate for the Quality.
DG Enterprise and Industry Approach on Combating Counterfeit Medicines Council of Europe Conference “Europe against Counterfeit Medicines” Session: Key.
Judie Finesilver MRPharmS e-Business Pharmacist Commercial Medicines Unit, Department of Health Update on barcodes.
NHS eProcurement Strategy Trade Association Meeting 24 th November 2014DH – Leading the nation’s health and care.
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
No /72, Level 2, Sri Balaji Mansion, Dr. Rajkumar Road, Rajajinagar 4th Block, Bangalore , India. Counterfeit Drug Detection | Fake Product.
Update on the MHRA/EMA & Wholesale Dealers Licence Legislation: PDIG Summer Symposium 14 th June, 2012 National Motor Cycle Museum East and South East.
Brand Protection: In the face of mounting counterfeiting, diversion & other infringements Jim Mentone | Director, Consumer Global Brand Protection.
The Impacts of Pharmaceutical & Retail Legislation Melvin Fletcher Datalinx Computer Systems.
preventing counterfeit …
Modernization of Informational Processes in Healthcare International Conference December 2013, Moscow The EDQM anti-counterfeiting Traceability service.
Mike Rose Vice President Johnson & Johnson Health Care Systems Inc.
GS1 standards – advantages and barriers in the produce of medicine Bratislava, 20. September 2007 Peter Vavro Logistics manager, Zentiva, a.s.
I&EHL: EU Pharmaceutical Law André den Exter
Pharmaceutical Track And Trace System in Turkey Case Study.
GS1 Healthcare Roadmap January 2015.
Barcoding in the supply chain
EU Directive 2001/83/EC Dr. P. V. Appaji, M.Pharm, Ph.D
Product Safety and Market Surveillance Package
The standard setting programme of the GPhC Priya Sejpal.
Falsified Medicines Directive Where are we now? WQPF 7 th November 2013 This presentation is the opinion and expression of Pharmallaney Ltd and does not.
GS1 US INITIATIVES UPDATE MARCH 18, GS1 STANDARDS MAKES IT POSSIBLE 2 SAFETYSECURITY VISIBILITYEFFICIENCY COLLABORATION To apply standards to business.
Polska The Central Loco workshop Budapest, 22 nd February 2007 Harmonisation of European logistic labels Grzegorz Sokołowski Institute of Logistics and.
Group KEVIN STEVEN EKAPUTRANTO RENDY WINARTA STEFANY TRIFOSA GLADYS NATALIA.
Saving Lives, Saving Money Lilia Bounab – Healthcare Sales Manager EMEA Ar ł amów hotel, 14-16th June 2015.
Monograph Development Process for the European Pharmacopoeia: How to participate in the work programme of the European Pharmacopoeia Dr Claude Coune Head.
Principles of quality control of registered medicines, non- registered medicines and counterfeits of medical products Jean-Marc Spieser, Head of Department.
Falsified medicines: a complex problem
GS1 DataMatrix Instructions
When Supply Chain meets Care Delivery: Background on GS1 and HL7 Ulrike Kreysa Director Healthcare, GS1 Global Office.
The Changing Face of EU Legislation Is the EU moving towards the FDA model of pharmaceutical legislation? By Robert Smith Director.
UNECE International Seminar Product Safety and Counterfeiting CEN WORKSHOP on Anti-Counterfeiting 6 November 2007.
Health and Food Safety Identification and authentication of medicines in Europe: What to expect in 2019 Patrizia Tosetti DG SANTE European Commission China/EU.
The Transposition of the Falsified Medicines Directive – the UK story
Mark Cilia Director Inspectorate & Enforcement 7 th May, 2014 Medicines Authority 203,Level 3, Rue D’Argens, Gzira,GZR 1368 Tel: (+356) Fax:
1 Summary of FDA Guidance for Industry Standards for Securing the Drug Supply Chain – Standardized Numerical Identification for Prescription Drug Packages.
External Provider Control
Verizon Intelligent Track and Trace: Serialization and Cold Chain
GS1 DataMatrix Instructions
Manufacturer Challenges
Update on EU regulatory developments
Falsified medicinal products
Healthcare Product Supply
Healthcare Product Supply Interoperability
[NAME OF PRESENTER] [TITLE OF PRESENTER] [COMPANY NAME]
Identification of Locations & Products in complex Supply Chains
EXPECTED EFFECTS OF SERIALIZATION SYSTEM IMPLEMENTING FROM THE STANDPOINT OF REGULATORY AUTHORITY 3-4 DECEMBER SHAKARYAN MKRTICH.
Healthcare Product Supply Interoperability
Pharmaceutical Track And Trace System in Turkey
The EU Falsified Medicines Directive: one year to go
ENTERPRISE RESOURCE PLANNING- ERP UNIT-1 INTRODUCTION Overview of Enterprise System Evolution Risks and Benefits Fundamental Technology Issues to be consider.
The Journey of Serialization and Traceability Brazil Market Deployment
Falsified Medicines Directive (FMD)
[NAME OF PRESENTER] [TITLE OF PRESENTER] [COMPANY NAME]
Last updated 4th November 2018
[NAME OF PRESENTER] [TITLE OF PRESENTER] [COMPANY NAME]
Falsified Medicines Directive The DDA 2018 Annual Conference
An industry perspective on FMD and Brexit Best practice 2018
13-14 August Maseru Lesotho
The Falsified Medicines Directive
PSS verification and validation
Presentation transcript:

EDQM anti-counterfeiting Traceability service for medicines

The eTACT project 1.Introduction  What is the background to the project?  EDQM proposal  Progress of the project  Benefits 2.Demo  Introduction  Live demo session ©2012 EDQM, Council of Europe, All rights reserved2

The eTACT project 1.Introduction  What is the background to the project?  EDQM proposal  Progress of the project  Benefits 2.Demo  Introduction  Live demo session ©2012 EDQM, Council of Europe, All rights reserved3

The Council of Europe ©2012 EDQM, Council of Europe, All rights reserved4 Core values: human rights pluralist democracy rule of law

European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe Directorate Convention on the Elaboration of a European Pharmacopoeia (1964) ©2012 EDQM, Council of Europe, All rights reserved5

CoE/EDQM anti-counterfeiting strategy ©2012 EDQM, Council of Europe, All rights reserved6 Inspection Testing MedicrimeCustoms

What is mass serialisation? Unique identifier  human readable  machine readable Distinguishes items from each other ©2012 EDQM, Council of Europe, All rights reserved7

Current situation: Point-of-Dispense verification ©2012 EDQM, Council of Europe, All rights reserved8 Verification at dispensing point Retail pharmacy Generation of item code Manufacture Distribution

Falsified Medicines Directive (FMD) Directive 2011/62 Safety features  Identifier that is readable by wholesale distributors and pharmacists  Tamper-proof device (outside scope of eTACT) ©2012 EDQM, Council of Europe, All rights reserved9

The eTACT project 1.Introduction  What is the background to the project?  EDQM proposal  Progress of the project  Benefits 2.Demo  Introduction  Live demo session ©2012 EDQM, Council of Europe, All rights reserved10

EDQM Traceability service - eTACT ©2012 EDQM, Council of Europe, All rights reserved11 Generation of UMI = Unique Medicine Identifier Verification of UMI Pharmacy Internet Mail-order Distribution Manufacture Verification of UMI Patients

Public governance  EDQM  Authorities  Confidentiality of data ©2012 EDQM, Council of Europe, All rights reserved12

Current situation: product coding ©2012 EDQM, Council of Europe, All rights reserved13 Mostly 1D barcode coding for product number only

Proposal for future coding ©2012 EDQM, Council of Europe, All rights reserved14 GTIN: product number

Proposal for future coding ©2012 EDQM, Council of Europe, All rights reserved15 Serial: randomised number

Proposal for future coding ©2012 EDQM, Council of Europe, All rights reserved16 Batch No.

Proposal for future coding ©2012 EDQM, Council of Europe, All rights reserved17 Expiry date: yymmdd

Proposal for future coding ©2012 EDQM, Council of Europe, All rights reserved18 NHRN: National Health Reimbursement Number (National Product Code if different from GTIN)

Unique Medicine Identifier (UMI) ©2012 EDQM, Council of Europe, All rights reserved19 All combine into a Unique Medicine Identifier = UMI

Manufacturers uploading UMIs ©2012 EDQM, Council of Europe, All rights reserved20 Queries from authenticated stakeholders and patients

Manufacturers not uploading UMIs ©2012 EDQM, Council of Europe, All rights reserved21 Queries from authenticated stakeholders and patients

Manufacturers not uploading UMIs ©2012 EDQM, Council of Europe, All rights reserved22 Queries from authenticated stakeholders and patients

Scope ©2012 EDQM, Council of Europe, All rights reserved23 Any pharmaceutical products Actors:  Any registered business stakeholders  Authorities  Patients 36 member states of the European Pharmacopoeia and beyond Secondary packaging

The eTACT project 1.Introduction  What is the background to the project?  EDQM proposal  Progress of the project  Benefits 2.Demo  Introduction  Live demo session ©2012 EDQM, Council of Europe, All rights reserved24

General overview of eTACT ©2012 EDQM, Council of Europe, All rights reserved25 Phase 1: Concept development 2a: System development Phase 2: Live demo 2010 – 2012 From b: Workshops Phase 3: Service development

The eTACT project 1.Introduction  What is the background to the project?  EDQM proposal  Progress of the project  Benefits 2.Demo  Introduction  Live demo session ©2012 EDQM, Council of Europe, All rights reserved26

Benefits Creates a harmonised approach  Inter-operable and flexible Protects confidentiality of data  Public governance Allows patients to verify their medicines ©2012 EDQM, Council of Europe, All rights reserved27

The eTACT project 1.Introduction  What is the background to the project?  EDQM proposal  Progress of the project  Benefits 2.Demo  Introduction  Live demo session ©2012 EDQM, Council of Europe, All rights reserved28

The eTACT project 1.Introduction  What is the background to the project?  EDQM proposal  Progress of the project  Benefits 2.Demo  Introduction  Live demo session ©2012 EDQM, Council of Europe, All rights reserved29

Aim of the workshops To show you the demo system simulating a supply chain Real Enterprise Resource Planning (ERP) and Point-of-Sales (PoS) Emulators Business intelligence tools ©2012 EDQM, Council of Europe, All rights reserved30

31©2012 EDQM, Council of Europe, All rights reserved To discuss  Technicalities  Project governance  Implementation strategy Aim of the workshops

32©2012 EDQM, Council of Europe, All rights reserved